January 2020 Br J Cardiol 2020;27:8–10 doi:10.5837/bjc.2020.001
Alexandros Georgiou, Nadia Yousaf
As discussed by Findlay and colleagues, ICI-related myocarditis is rare but potentially fatal. Its true incidence remains unknown but data from a single cancer registry study from the USA suggests a prevalence of 1.14% with fatality rates as high as 50%.4,5 Data suggest that myocarditis is an early ICI-toxicity, typically seen within the first three months of starting treatment, and is more common in patients treated with combination anti-CTLA-4 and anti-PD1 blockade. The prevalence of myocarditis in patients treated with chemotherapy and anti-PD1 or tyrosine kinase Inhibitors (TKI) and anti-PD1 combinations has not been described. Identifyin
July 2017 Br J Cardiol 2017;24:108–12 doi:http://doi.org/10.5837/bjc.2017.019 Online First
Alex Asher
Introduction Endomyocardial biopsy (EMB) was first pioneered in 1962 in Japan.1 Since then EMB has undergone significant advances in procedural equipment and tissue analysis.2,3 Using a combination of histological, immunohistochemical and viral analysis, a variety of myocardial disorders can be detected. The procedure involves taking four or more biopsy samples from the right intraventricular septum using flexible bioptomes, under fluoroscopic or echocardiographic guidance.4 Routine access is typically via a sheath inserted into the right internal jugular or femoral vein. Left ventricular biopsy can also be performed via the femoral arteries
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits